X4 Pharmaceuticals Q3 revenue rises on XOLREMDI sales
XFOR•X4 Pharmaceuticals said third-quarter revenue rose year over year, driven by higher XOLREMDI sales, while its net loss narrowed to $20.20 million. The company secured a $150 million loan facility and expects its cash runway to extend into the first quarter of 2029.
1. Quarterly results
X4 Pharmaceuticals reported higher third-quarter revenue year over year, driven by increased XOLREMDI sales. Its net loss narrowed to $20.20 million, and income from operations was a loss of $19.99 million. Operating expenses totaled $22.87 million.
2. Cash and trial outlook
The company secured a $150 million loan facility and said its cash runway is expected to extend into the first quarter of 2029. It expects to complete enrollment in the 4WARD trial in the fourth quarter of 2026, with topline data due in the first quarter of 2028. Enrollment of the first participant in the 4STEPS Phase 2b trial is expected in the first quarter of 2027.
